The investment seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the FLAGLSX-Forensic Accounting Long-Short Index. The investment seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the FLAGLSX-Forensic Accounting Long-Short Index.
SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...
SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in High-Grade Glioma.Presented data supporting RTNova (CLD-400), the company’s...
- RTNova, an innovative systemic antitumor enveloped virotherapy, unlocks new possibilities in cancer therapy - RTNova addresses challenges posed by untargetable and untreatable metastatic...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0679 | -7.18518518519 | 0.945 | 0.9471 | 0.83 | 940928 | 0.90639147 | CS |
4 | -0.4929 | -35.9781021898 | 1.37 | 1.53 | 0.818 | 1234971 | 1.18195695 | CS |
12 | -0.2629 | -23.0614035088 | 1.14 | 3.89 | 0.818 | 1905922 | 2.07151765 | CS |
26 | -1.0129 | -53.5925925926 | 1.89 | 3.89 | 0.73 | 1006144 | 1.93710925 | CS |
52 | -10.3229 | -92.16875 | 11.2 | 16.8 | 0.73 | 1039853 | 2.57505104 | CS |
156 | -44.2229 | -98.055210643 | 45.1 | 50 | 0.73 | 784814 | 3.03453305 | CS |
260 | -44.2229 | -98.055210643 | 45.1 | 50 | 0.73 | 784814 | 3.03453305 | CS |
銘柄コード | 株価 | 出来高 |
---|---|---|
EONREON Resources Inc | US$ 1.33 (30.39%) | 133.45M |
MSTUT Rex 2X Long MSTR Daily Target ETF | US$ 12.685 (-3.39%) | 66.6M |
SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 33.69 (3.69%) | 60.46M |
SPXSDirexion Daily S&P 500 Bear 3X Shares New | US$ 5.79 (-2.53%) | 52.66M |
TSLZT Rex 2X Inverse Tesla Daily Target ETF | US$ 2.13 (1.43%) | 48.58M |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約